Market Place
Sourcing Support
Tris Pharma Expands Global Availability of ADHD Treatments
19 Nov 2024 //
BUSINESSWIRE
Tris Pharma`s ONYDA XR For ADHD Now Available In US
01 Oct 2024 //
BUSINESSWIRE
Tris Pharma Promotes Manesh Naidu to Chief Commercial Officer
17 Sep 2024 //
BUSINESSWIRE
Tris Pharma`s Cebranopadol Shows Prolonged Pain Relief at PAINWeek 2024
03 Sep 2024 //
BUSINESSWIRE
Tris Pharma Starts Phase 3 Trials For Novel Pain Treatment Cebranopadol
22 Aug 2024 //
BUSINESSWIRE
Tris Pharma Presents Data On Cebranopadol For Pain Treatment
06 Aug 2024 //
BUSINESSWIRE
Tris Pharma To Present Pain Therapy Data At IASP 2024 Congress
30 Jul 2024 //
BUSINESSWIRE
Tris Pharma captures FDA nod for non-stimulant ADHD treatment Onyda XR
30 May 2024 //
FIERCE PHARMA
Tris Pharma Appoints Michael Magee as Vice President, Quality & Compliance
07 Feb 2024 //
BUSINESSWIRE
Tris Pharma Appoints Franchesca Fowler to Chief Compliance Officer
22 Jan 2024 //
BUSINESSWIRE
Tris Pharma Partners with Perigon Pharmacy 360
30 Oct 2023 //
BUSINESSWIRE
Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension
25 Sep 2023 //
BUSINESSWIRE
Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Cebranopadol
05 Sep 2023 //
BUSINESSWIRE
Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio
02 May 2023 //
BUSINESSWIRE
Tris Pharma previews plans for pain drug with reduced abuse potential
17 Jan 2023 //
CLINICAL TRIALS ARENA
Tris Pharma Reports Positive Topline Data from Clinical Study of Cebranopadol
13 Dec 2022 //
PRNEWSWIRE
Tris Pharma Announces Acquisition of New, Late-Stage Drug Candidate for Pain
07 Dec 2022 //
PRNEWSWIRE
Tris & Pediatrix to Expand Partnership to Commercialize ADHD Portfolio
01 Dec 2022 //
PRNEWSWIRE
Tris Pharma Announces Continued Supply and Availability of DYANAVEL Tablets
19 Oct 2022 //
PRNEWSWIRE
Tris`s Generic Dextroamphetamine Sulfate Receives Approval in the U.S.
18 Aug 2022 //
FDA
Tris Pharma Announces US District Court Upholds Validity of QuilliChew ER
18 Aug 2022 //
PRNEWSWIRE
Tris Pharma Announces Availability of New DYANAVEL XR Tablets for ADHD
16 Aug 2022 //
PRNEWSWIRE
Tris Pharma Announces Development of Oxybate Formulation
27 Jul 2022 //
PRNEWSWIRE
Tris Pharma Announces Publication of Study Results of DYANAVEL XR in ADHD
22 Jul 2022 //
PRNEWSWIRE
Tris Pharma`s Generic Potassium Chloride Receives Approval in U.S.
26 Jan 2022 //
FDA
Tris Pharma`s Generic Sildenafil Citrate Receives Approval in the US
17 Nov 2021 //
FDA
FDA Approves Tris` DYANAVEL XR Once-Daily Extended-Release Tablets, for ADHD
05 Nov 2021 //
PRNEWSWIRE
Tris pharma`s Generic Droxidopa Receives Approval In US
11 May 2021 //
FDA
Tris Pharma® Announces Acquisition of Park Therapeutics - Pain Company
29 Apr 2021 //
PRNEWSWIRE
Tris Pharma® Announces Acquisition of Park Pain Company with First-In-Class
29 Apr 2021 //
BIOSPACE
Tris Pharma and Athena Bioscience Announce Exclusive License Agreement
22 Feb 2021 //
PRNEWSWIRE
Tris Pharma Presents Positive Results from Phase 3 Study of Amphetamine
20 Jan 2021 //
PRNEWSWIRE
Tris Pharma Presents Positive Results from Phase 3 Study of Amphetamine
20 Jan 2021 //
PRNEWSWIRE
Tris Pharma to Debut Amphetamine Extended-Release Tablet Efficacy
15 Jan 2021 //
PRNEWSWIRE
Tris & Neuraxpharm Group Announce Partnership to Tris` Quillivant XR
08 Dec 2020 //
PRNEWSWIRE
Tris Pharma and Medison Pharma Announce Exclusive License Agreement
17 Nov 2020 //
BIOSPACE
Tris Pharma Launches New ADHD Portfolio Website for Patients and Caregivers
10 Nov 2020 //
PRNEWSWIRE
Tris Pharma to Present Amphetamine Extended-Release Tablet Data
23 Oct 2020 //
PRNEWSWIRE
Tris Pharma to Present Amphetamine Extended-Release Tablet Data
22 Oct 2020 //
PRNEWSWIRE
Tris Pharma to Present Amphetamine Extended-Release Tablet Data
21 Oct 2020 //
PRNEWSWIRE
Tris Pharma Launches its Scientific Advisory Board
06 Oct 2020 //
PRNEWSWIRE
Tris Pharma, KYE Pharmaceuticals Enter ADHD Product Alliance
09 Jul 2020 //
CONTRACTPHARMA
Tris Pharma and KYE Pharmaceuticals Announce Exclusive License Agreement
08 Jul 2020 //
PRNEWSWIRE
Enforcement Report - Week of July 31, 2019
31 Jul 2019 //
FDA
Dr. Reddy`s expands recall of infants` ibuprofen
06 Feb 2019 //
FIERCE PHARMA
Enforcement Report - Week of December 26, 2018
26 Dec 2018 //
FDA
Tris Pharma recalls potentially harmful infants` ibuprofen
08 Dec 2018 //
FIERCE PHARMA
Tris Pharma Presents Clinical Data for DYANAVEL® XR (amphetamine)
11 Nov 2018 //
PR NEWSWIRE
Tris Pharma Receives FDA Warning Letter
11 Apr 2018 //
FDA
CMO for Pfizer ADHD drug hit with US FDA warning
10 Apr 2018 //
IN PHARMATECHNOLOGIST
Enforcement Report - Week of September 6, 2017
06 Sep 2017 //
FDA
Vernalis cough and cold drug knocked-back by FDA
08 Aug 2017 //
PHARMAFILE
Enforcement Report - Week of March 29, 2017
29 Mar 2017 //
FDA
Tris Pharma`s Generic Morphine Sulfate approved in US to treat pain
18 May 2016 //
FDA
Tris Pharma`s Generic Gabapentin approved in US as an antiepileptic drug
14 Mar 2016 //
FDA
Tris Pharma`s Generic Potassium Chloride approved in US for Hypokalemia
04 Mar 2016 //
FDA
FDA accepts Tris Pharma`s Dyanavel XR NDA for review
21 May 2015 //
NEWS MEDICAL
